MorningMed is a community of 814,300 medical professionals

We're a place where medical professionals share news and other news items to help their peers stay up to date

All articles tagged: Arthropathic psoriasis, unspecified (L40.50)

HealthDay 01 July at 03.16 PM

Psoriasis, With or Without Psoriatic Arthritis, Associated With Fatigue

Psoriasis is associated with fatigue, especially among those with psoriatic arthritis (PsA), according to a study published in the July issue of the Journal of the American Academy of Dermatology.Lea Nymand, from Bispebjerg Hospital and the University of Copenhagen in Denmark, and colleagues explored the characteristics of fatigue and it

HealthDay 21 June at 11.00 PM

FDA Expands Pediatric Indication for Rinvoq

The U.S. Food and Drug Administration has expanded indications for Rinvoq (upadacitinib) to now include pediatric patients (ages 2 years and older) with polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis (PsA).Rinvoq is indicated for pediatric patients with an inadequate response or intolerance to one or more tumor necros

HealthDay 30 December at 04.59 AM

Model Predicts New Psoriatic Arthritis in People With Psoriasis

The development of psoriatic arthritis (PsA) can be predicted with reasonable accuracy for psoriasis patients, according to a study published online Aug. 9 in Arthritis & Rheumatology.Lihi Eder, M.D., Ph.D., from University of Toronto, and colleagues developed a risk prediction model (<a href="http://sharpmindtill120.x10host.co

HealthDay 29 December at 04.10 PM

Biological Agent Trials for Psoriasis Rarely Include Patient Images

Few randomized controlled trials involving biological agents for psoriasis treatment include patient images, according to a review published online Nov. 15 in the Journal of Dermatological Treatment.Sam Polesie, M.D., Ph.D., from the University of Gothenburg in Sweden, and colleagues conducted a systematic review to assess the proportio

HealthDay 02 November at 11.00 PM

FDA Approves Wezlana for Multiple Inflammatory Diseases

The U.S. Food and Drug Administration has approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory diseases.&nbsp;The approval includes indications for adults with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic a